SLXNW Silexion Therapeutics Corp Warrant

XNAS
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

SLXNW — —
Key stats
About
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
Exchange
XNAS
Employees
13
List Date
2024-08-16
CIK
0002022416
Headquarters
Ramat Gan, L3
Homepage
https://silexion.com

Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interf…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'24'25'26Avg
Jan--230.68%-1.54%114.57%
Feb---24.81%-18.87%-21.84%
Mar--27.50%-40.29%-6.39%
Apr---6.82%0.71%-3.06%
May---20.97%4.40%-8.29%
Jun---16.81%36.94%10.06%
Jul--5.25%-20.32%-7.54%
Aug-5.22%3.53%-18.13%-6.61%
Sep-60.42%0.28%-54.87%-38.34%
Oct51.65%27.48%94.74%*57.96%
Nov-63.70%-32.89%---48.30%
Dec55.50%-13.62%--20.94%
Total-67.89%56.82%-60.63%-23.90%
* Only 3 year(s) of data available.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $0.01
SMA 50: $0.01
SMA 200: $0.03
Current: $0.01
EMA 12: $0.01
EMA 26: $0.01
MACD: -0.0013 | Signal: 0.0010
BEARISH
ADX (14): 18.38
RANGE
+DI: 47.66
−DI: 16.79

Momentum Oscillators

RSI (14): 63.00
NEUTRAL
Stoch %K: 36.46
Stoch %D: 23.22
Williams %R: -28.99

Volume & Volatility

BB Upper: $0.01
BB Lower: $0.00
OVERBOUGHT
OBV: 1,306,252
Vol SMA 20: 68,283
Vol ROC: 12168.18%
ATR: $0.00
True Range: $0.01
HV 20: 462.1%
HV 30: 389.2%
HV 60: 433.4%

Data Summary

Data Points: 432
Last Updated:
Date Range: 2024-08-16T00:00:00 – 2026-10-21T00:00:00
AI Analysis

LLM Stock Analysis Report: SLXNW

Executive Summary

Overall assessment: NEUTRAL (confidence level: 6/10)

Key drivers:

  • Strong technical signals indicating a potential uptrend
  • Positive news sentiment surrounding recent developments in the company's clinical trials and financial performance
  • High volatility, which may impact trading decisions

Primary risks:

  • Elevated beta value, indicating high risk relative to market
  • Limited options activity, making it challenging to gauge institutional interest

Investment thesis: SLXNW has the potential for short-term gains as technical indicators align with positive news sentiment. However, high volatility and limited options data make it essential to closely monitor trading activity and adjust positions accordingly.

Recent news sentiment impact: The company's recent positive developments have contributed to a neutral-to-bullish sentiment, which may continue to support the stock's price in the short term.

Technical Analysis

Trend Direction: Short-term (1-4 weeks): Uptrend; Medium-term (1-3 months): Uptrend; Long-term (3-12 months): Neutral

Support/Resistance Levels:

  • SMA 20: $0.02
  • SMA 50: $0.02
  • SMA 200: $0.03
  • Upper Bollinger Band: $0.02

Momentum Signals:

  • RSI interpretation: Neutral (45.25)
  • MACD signal: Bearish (negative histogram)
  • Bollinger Bands position: Neutral (signal line at middle band)

Volume Analysis:

  • Volume SMA 20: 10433.15
  • On-Balance Volume (OBV): 1144030.00
  • Volume Rate of Change: -91.66%

News & Sentiment Analysis

Recent Headlines Summary: The company has announced several positive developments, including the initiation of GMP clinical supply manufacturing and approval of a phase 2/3 trial.

Sentiment Assessment: Positive (aggregate sentiment from last 10 news articles)

Catalyst Identification: Upcoming earnings release, potential regulatory approvals

Market Narrative: The recent news has aligned with technical signals, indicating a potential uptrend. However, high volatility and limited options data make it essential to closely monitor trading activity.

Risk & Volatility Assessment

Beta Interpretation: High risk relative to market (beta: 4.40)

Volatility Regime: Current vs historical volatility levels: High

Options Market Signals: No options data available

Downside Protection: Support levels and risk management considerations: SMA 20 ($0.02), SMA 50 ($0.02), Bollinger Band lower boundary ($0.01)

Market Context & Positioning

Sector Performance: Relative strength vs sector/market: Neutral (Pancreatic Cancer treatment sector)

Institutional Activity: Volume patterns suggesting institutional interest: Limited options activity, no clear trends

Correlation Analysis: How stock moves relative to market (R-squared interpretation): 0.17 (weak correlation)

Relative Valuation: Position within trading range: Neutral

Key Levels & Action Items

Critical Price Levels:

  • SMA 20 ($0.02)
  • SMA 50 ($0.02)
  • Upper Bollinger Band ($0.02)

Breakout/Breakdown Levels:

  • Critical price levels mentioned above
  • MACD signal line crossover: Bearish (negative histogram)

Time-Sensitive Catalysts: Upcoming earnings release, potential regulatory approvals

Risk Management: Stop-loss levels and position sizing considerations: SMA 20 ($0.02), SMA 50 ($0.02), Bollinger Band lower boundary ($0.01)

Generated
News
All SLXNW news →

SLXNW Options Activity & IV Rank

Loading options activity...
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis

Risk Metrics

Beta: 2.5161
Alpha: 492.08%
Correlation: 0.0866
R-Squared: 0.8%
Stock Volatility: 390.4%
Market Volatility: 13.4%

Analysis Details

Benchmark: SPY
Data Points: 185
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time

SLXNW Institutional Ownership (13F)

Latest filings — 2026-06-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

20 filers2,430,939 shares$99.03K value
# Filer Shares Value % of Total % of Float Period
1 Oasis Management Co Ltd. 11,111 $28.33K 28.61% — 2026-06-30
2 Polar Asset Management Partners Inc. 743,475 $20.82K 21.02% — 2026-06-30
3 Linden Advisors LP 337,500 $9.48K 9.58% — 2026-06-30
4 ARISTEIA CAPITAL, L.L.C. 236,546 $6.63K 6.70% — 2026-06-30
5 Clear Street Group Inc. 218,165 $6.63K 6.70% — 2026-06-30
6 SECURITY BENEFIT LIFE INSURANCE CO /KS/ 150,000 $4.56K 4.60% — 2026-06-30
7 Goldman Sachs Group Inc Custodian 125,103 $3.80K 3.84% — 2026-06-30
8 Kepos Capital LP 100,000 $3.00K 3.03% — 2026-06-30
9 Susquehanna International Group, LLP Custodian 92,073 $2.80K 2.83% — 2026-06-30
10 Jane Street Group, LLC Custodian 74,910 $2.28K 2.30% — 2026-06-30
11 PICTON MAHONEY ASSET MANAGEMENT 57,175 $1.74K 1.76% — 2026-06-30
12 Context Capital Management, LLC 51,183 $1.56K 1.57% — 2026-06-30
13 TENOR CAPITAL MANAGEMENT Co., L.P. 50,000 $1.52K 1.53% — 2026-06-30
14 GABELLI & Co INVESTMENT ADVISERS, INC. 38,150 $1.16K 1.17% — 2026-06-30
15 Mint Tower Capital Management B.V. 25,000 $1.00K 1.01% — 2026-06-30
16 DUPONT CAPITAL MANAGEMENT CORP 32,500 $988 1.00% — 2026-06-30
17 Neuberger Berman Group LLC 31,552 $959 0.97% — 2026-06-30
18 GABELLI FUNDS LLC 30,496 $927 0.94% — 2026-06-30
19 Stifel Financial Corp Custodian 16,000 $486 0.49% — 2026-06-30
20 COBBLESTONE CAPITAL ADVISORS LLC /NY/ 10,000 $352 0.36% — 2025-09-30
2 filers$36.55K notional
# Filer Notional Value % of Total Period
1 DeepCurrents Investment Group LLC $36.17K 98.96% 2026-06-30
2 Millennium Management LLC Custodian $380 1.04% 2026-06-30
# Filer Notional Value % of Total Period

SLXNW Insider Trading (Form 4)

Latest: 2026-06-08
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-06-08 Hadar Mirit Horenshtein CFO and Secretary Award (A) +7,500 — EDGAR
2026-06-08 Mitchell Shirvan CSO and CDO Award (A) +6,000 — EDGAR
2026-06-08 Ilan Hadar Chairman and CEO Award (A) +10,000 — EDGAR
2026-03-30 Mitchell Shirvan CSO and CDO Sell (S) −22,818 $1.36 -$31.0K EDGAR
2026-02-25 Shlomo Noy Director Award (A) +9,091 — EDGAR
2026-02-23 Dror Yosef Abramov Director Award (A) +9,091 — EDGAR
2026-02-23 Ilan Hadar Chairman and CEO Award (A) +64,350 — EDGAR
2026-02-23 Ruth Alon Director Award (A) +9,091 — EDGAR
2026-02-23 Mitchell Shirvan CSO and CDO Award (A) +49,726 — EDGAR
2026-02-23 Hadar Mirit Horenshtein CFO and Secretary Award (A) +49,726 — EDGAR
2026-02-23 Amnon Peled Director Award (A) +7,576 — EDGAR
2026-02-23 Avner Lushi Director Award (A) +9,091 — EDGAR
2026-01-27 Ilan Levin Director Mixed +888,900 $4.00 $3.60M EDGAR
2025-12-31 Avner Lushi Director Award (A) +1,587 — EDGAR
2025-12-31 Dror Yosef Abramov Director Award (A) +794 — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

SLXNW Insider Holdings

9 insiders · @ $0.01
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Ilan Levin Director 456,970 $6.8K $0 1 2026-01-27
2 Shlomo Noy Director 25,399 $376 $0 2 2026-02-25
3 Avner Lushi Director 25,399 $376 $0 2 2026-02-23
4 Ilan Hadar Chairman and CEO 16,547 $245 $0 2 2026-06-08
5 Hadar Mirit Horenshtein CFO and Secretary 12,515 $185 $0 2 2026-06-08
6 Ruth Alon Director 10,228 $151 $0 2 2026-02-23
7 Dror Yosef Abramov Director 10,180 $151 $0 2 2026-02-23
8 Mitchell Shirvan CSO and CDO 8,789 $130 -$31.0K 3 2026-06-08
9 Amnon Peled Director 8,237 $122 $0 2 2026-02-23
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.